At present, innovative drugs are becoming a pharmaceutical subdivision track
that is highly concerned and optimistic in the industry.
Affected by multiple resonances such as favorable policies, capital increases, and talent returns, the domestic innovative drug industry has developed rapidly in recent years, and the market size has been expanding, from 799 billion yuan in 2017 to 963.
9 billion yuan in 2020, with an annual compound growth rate of 6.
45%.
The industry expects that by 2022, this market is expected to exceed 1,000 billion yuan, reaching 1,148.
4 billion yuan
.
At present, with the acceleration of the approval of new drugs in China, a large number of innovative drugs and new indications are being approved for listing at an accelerated pace
.
In the first half of the year, the State Food and Drug Administration approved a total of more than 30 new drugs on the market, 9 of which are domestic innovative drugs, of which cardunil is the country's first PD-1/CTLA-4 double antibody, which has obvious advantages in cervical cancer indications, and has large indications in the rapid advancement
.
Tigoras is the first domestic P-VAB drug with indications for reflux esophagitis
.
In addition, in the first half of the year, 10 domestic innovative drugs such as sindilizumab, sugli maclizumab, and voltemerinib were approved for new indications
.
At the same time, many innovative drug products have gradually entered the volume release period
.
For example, BeiGene mentioned in the 2022 interim report that its BTK inhibitor zebutinib has been approved for listing in more than 50 countries and regions around the world, and global sales in the first half of the year reached 1.
514 billion yuan, a year-on-year increase of 262.
9%.
In addition to zebutinib capsules, there are also many domestic innovative drugs that are being pulled by entering medical insurance after the market, such as Ametinib mesylate tablets from Howsen, and edarafeng dexterol injection concentrated solution of Simcere
Pharmaceuticals.
Among them, GF Securities expects the peak sales of Ametinib mesylate tablets in Howsen is expected to reach 5 billion yuan
in 2024.
Simcere Pharmaceutical said that innovative drugs have become the main source of revenue for the group, with revenue of about 1.
767 billion yuan in the first half of the year, an increase of 44.
8% year-on-year, accounting for a record high of 65.
4%
in the proportion of total revenue in the same period.
Among them, the sales revenue of Serbicin (concentrated solution for edarafen dexterol injection) increased
.
Under the active layout, the performance of some pharmaceutical companies on the innovative drug track is ushering in explosive growth
.
For example, China Biopharmaceutical Report shows that new products, innovative drugs and oncology drugs have become the company's second growth curve, of which the revenue of innovative drugs totaled 3.
49 billion yuan, an increase of 14.
2% year-on-year, accounting for 22.
9%
of revenue.
The company expects that by 2030, the revenue share of innovative drugs will increase to 60
%.
Hansen's revenue from innovative drugs in the first half of the year was about 2.
321 billion yuan, an increase of about 84.
8% year-on-year, and its proportion of revenue increased significantly to about 52.
3%, setting a new high
.
In addition, it is worth mentioning that under the rapid development of the innovative drug industry, the CXO industry of pharmaceutical water sellers has also ushered in explosive growth
.
Among them, the net profits of the head companies WuXi AppTec and WuXi Biologics in the first half of the year increased by 68.
5% and 63.
5% respectively, exceeding market expectations, and the dynamic valuation was significantly reduced; Gloria Ying and Boteng shares have also achieved remarkable results
.
Among them, The semi-annual report recently released by Gloria Ying shows that the revenue in the first half of the year was 5.
041 billion yuan; an increase of 186.
4% year-on-year, and the net profit attributable to the mother was 1.
74 billion yuan, an increase of 305.
31%
year-on-year.
The industry believes that with the continuous improvement of the domestic pharmaceutical outsourcing rate and the increase in market penetration, there is still a lot of room for growth in the domestic market, and the head enterprises are expected to get opportunities
.
The report predicts that the compound annual growth rate of domestic CXO will be between 25% and 35% in the next five years, which is much higher than the global average of
9%.
In the future, domestic CXO may become an important player
in global innovative drugs.
